Sulzer reported strong 2025 results, exceeding profit expectations with a record CHF 556 million EBITDA and a 15.6% operating margin, up from the analyst consensus of 15.1%. Sales reached CHF 3.55 billion, a 5.6% increase, driving an 18% adjusted EBITDA rise.

The company's Chemtech division showed a 19% order intake recovery. For 2026, Sulzer guided organic order intake growth of 1% to 5% and sales growth of 2% to 5%, targeting an EBITDA margin of approximately 16.5%, a 85 basis point improvement.